Exploratory Study to Explore the Safety and Efficacy of the HDx Therapy Using Theranova 500 Dialyzer in Comparison to Hemodiafiltration
Not Applicable
Completed
- Conditions
- End Stage Renal Disease
- Interventions
- Device: HemodiafiltrationDevice: Theranova 500 medium cut-off dialyzer
- Registration Number
- NCT03499691
- Lead Sponsor
- Vantive Health LLC
- Brief Summary
Today it is well established that middle molecules comprise several compounds that are not effectively removed by high-flux dialyzers, and effective clearance of large middle molecules in the process of dialysis depends on the dialyzer membrane having large enough pore sizes, larger than the conventional high-flux dialyzers. Studies have found associations between levels of large middle molecule uremic toxins and immune dysfunction and inflammation, as well as adverse outcomes. This indicates that dialysis membranes having larger pores, enabling an expanded HD (HDx) with more effective removal of large middle molecules, can have a positive impact on the inflammatory state. While data is starting to appear on the long-term use of the HDx therapy, little is still known on how large middle molecules and inflammation markers are affected over time.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 43
Inclusion Criteria
- ESRD patients age between 18 - 80 years
- Clinically stable as judged by the treating physician for 30 days prior to enrollment, as demonstrated by pertinent patient medical history, physical examination, and laboratory testing
- Hemodialysis therapy with HDF for at least 3 months immediately prior to study enrollment
Exclusion Criteria
- No informed consent provided
- Significant psychiatric disorder, mental disability, or other condition that may interfere with the patient's ability to provide informed consent
- Pregnant, breastfeeding, or planning to become pregnant
- Unstable vascular access associated with risk of low and variable extracorporeal blood flow rate (QB)
- Chronic liver disease, known paraprotein-associated disease, known bleeding disorders (e.g., gastrointestinal bleed, colonic polyps, small bowel angiodysplasia and active peptic ulcers)
- Major bleeding episode (i.e. soft tissue bleeding, blood in stool, joint damage, retinal bleeding, extensive mucosal bleeding, exsanguination, cerebral hemorrhage) ≤ 12 weeks prior to enrollment
- Blood (red blood cell) transfusion ≤ 12 weeks prior to enrollment
- Clinical signs of acute infection ≤ 4 weeks prior to enrollment
- Active cancer, except for basal cell or squamous cell skin cancer
- Positive serology test for human immunodeficiency virus or hepatitis infection
- Scheduled for planned interventions requiring hospitalization > 1 week
- Scheduled for living-donor transplantation within the study period
- Currently participating in another interventional clinical study or has participated in another interventional clinical study in the past 3 months that may interfere with this study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Hemodiafiltration (HDF) Therapy Hemodiafiltration Patients will undergo 3 dialysis sessions per week with on-line HDF for up to 24 weeks. Expanded Hemodialysis (HDx) Therapy Theranova 500 medium cut-off dialyzer Patients will undergo 3 dialysis sessions per week with Theranova 500 for up to 24 weeks.
- Primary Outcome Measures
Name Time Method Reduction ratios of fibroblast growth factor 23 (FGF-23) Week 12 Reduction ratios of lambda immunoglobulin free light chains (λ-FLC) Week 12 Reduction ratios of chitinase-3-like protein 1 (YKL-40) Week 12 Reduction ratios of kappa immunoglobulin free light chains (k-FLC) Week 12 Reduction ratios of serum beta-2 microglobulin (β2M) Week 12
- Secondary Outcome Measures
Name Time Method Percent change from pre- to post-dialysis in mid-week serum levels of IL-6 Week 12 Change from baseline in mid-week pre-dialysis serum levels of λ-FLC, κ-FLC, YKL-40, FGF-23, ß2M Week 12 and 24 Transferrin Saturation (TSAT) Baseline, Week 12, Week 24 24-hour urine output on monthly basis Month 1, Month 2, Month 3, Month 4, Month 5, Month 6 Erythropoiesis stimulating agent (ESA) responsiveness Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 Total patient death Week 1 through Week 24 Change from baseline in mid-week pre-dialysis serum level of fibrinogen Week 12 and 24 Change from baseline in mid-week pre-dialysis serum levels of pentraxin-3 (PTX-3), high sensitivity C-reactive protein (hs-CRP), interleukin (IL-6), and interleukin-10 (IL-10) Week 12 and 24 Percent change from pre- to post-dialysis in mid-week serum levels of PTX-3 Week 12 Percent change from pre- to post-dialysis in mid-week serum levels of IL-10 Week 12 Change from baseline in mid-week pre-dialysis serum level of albumin Week 12 and 24 Serum phosphorous Week 24 Dialysis Symptom Index (DSI) Baseline, Week 12, Week 24 Number of adverse events of hospitalization, cardiovascular events, and infective episodes Week 1 through Week 24 Intravenous iron dosage Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 Percent change from pre- to post-dialysis in mid-week serum levels of hs-CRP Week 12 Single pool Kt/Vurea Week 24 Kidney Disease Quality of Life 36 (KDQOL-36) Baseline, Week 12, Week 24 Serum ferritin Baseline, Week 12, Week 24 Hemoglobin levels Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 ESA dosage by type, administration frequency, and route Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24
Trial Locations
- Locations (1)
RTS Murcia VII, RTS Servicios de Diálisis S.L.U.
🇪🇸Murcia, Spain